Caris Life Sciences (CAI) Shares Outstanding (Weighted Average) (2024 - 2026)

Caris Life Sciences' Shares Outstanding (Weighted Average) history runs 3 years deep, the most recent figure standing at $282.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 693.2% year-over-year to $282.6 million; the TTM figure through Mar 2026 stood at $282.6 million (up 693.2% YoY), while the FY2025 annual figure was $167.2 million, up 371.04% from the prior year.
• Shares Outstanding (Weighted Average) was $282.6 million for Q1 2026 at Caris Life Sciences, up from $167.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $282.6 million in Q1 2026 to a low of $35.4 million in Q2 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $96.3 million across 3 years, with a median of $43.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Weighted Average) jumped 42.34% in 2025, then soared 693.2% in 2026.
• A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $35.5 million in 2024, then soared by 371.04% to $167.2 million in 2025, then surged by 68.99% to $282.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $282.6 million (Q1 2026), $167.2 million (Q4 2025), and $128.4 million (Q3 2025), per Business Quant data.